Abivax (AAVXF) Accounts Payables (2022 - 2025)

Abivax has reported Accounts Payables over the past 4 years, most recently at $43.7 million for Q4 2025.

  • Quarterly results put Accounts Payables at $43.7 million for Q4 2025, down 6.66% from a year ago — trailing twelve months through Dec 2025 was $43.7 million (down 6.66% YoY), and the annual figure for FY2025 was $42.4 million, down 10.55%.
  • Accounts Payables for Q4 2025 was $43.7 million at Abivax, down from $46.8 million in the prior quarter.
  • Over the last five years, Accounts Payables for AAVXF hit a ceiling of $50.8 million in Q4 2023 and a floor of $15.8 million in Q4 2022.
  • Median Accounts Payables over the past 4 years was $45.3 million (2024), compared with a mean of $39.3 million.
  • Biggest five-year swings in Accounts Payables: skyrocketed 221.8% in 2023 and later decreased 7.83% in 2024.
  • Abivax's Accounts Payables stood at $15.8 million in 2022, then skyrocketed by 221.8% to $50.8 million in 2023, then dropped by 7.83% to $46.8 million in 2024, then dropped by 6.66% to $43.7 million in 2025.
  • The last three reported values for Accounts Payables were $43.7 million (Q4 2025), $46.8 million (Q4 2024), and $50.8 million (Q4 2023) per Business Quant data.